MFMelissa Alexandre Fernandes

Melissa Alexandre Fernandes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa Alexandre Fernandes has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Upskilling in Healthy Longevity Medicine and Its Association With Physicians’ Implementation Intent and Self-Reported Clinical Confidence: Cross-Sectional Observational Study

    by Evelyne Bischof, Dominika Wilczok, James L Kirkland, Bhirau Wilaksono, Christine Yuan Huang, Suwanna Suwannaphong, Wanviput Sanphasitvong, Dalila Čamdžić, Carolina Hernandez, Yoko Madea, et al.

  • Open Access

    Upskilling in Healthy Longevity Medicine and Its Association With Physicians’ Implementation Intent and Self-Reported Clinical Confidence: Cross-Sectional Observational Study

    by Evelyne Bischof, Dominika Wilczok, James L Kirkland, Bhirau Wilaksono, Christine Yuan Huang, Suwanna Suwannaphong, Wanviput Sanphasitvong, Dalila Čamdžić, Carolina Hernandez, Yoko Madea, et al.

    Background: Structured educational programs for physicians in healthy longevity medicine (HLM) remain scarce. No published data yet document the impact of longevity-focused medical education on physicians. This study assesses the ramifications of the HLM curriculum, certified by the American Council for Continuing Medical Education, on physicians’ confidence in their knowledge of HLM and clinical practice. Objective: This study aimed to evaluate the impact of accredited HLM education on physicians’ confidence in knowledge and practice patterns, examining self-reported integration of HLM principles, professional attitudes, and career trajectories to determine the translational value of structured curricula in the emerging medical discipline. Methods: A cross-sectional online survey was conducted between March and April 2024 among physicians who had completed accredited HLM courses between January 2023 and February 2024. Invitations were sent globally to 590 eligible physicians; trainees and students were excluded. A total of 113 (19.2%) respondents completed the survey and were included in the analysis. The survey assessed self-reported changes in clinical implementation, confidence in HLM-related knowledge, and professional attitudes following course completion. Descriptive statistics and logistic regression analyses were performed ( P <.05). Results: Respondents represented 42 nationalities and were primarily trained in family medicine (n=31, 27.4%) and internal medicine (n=18, 15.9%). Overall, 96.5% (n=99) of the respondents reported increased confidence in HLM-related knowledge, with 47.8% (n=55) indicating substantial improvement. More than half of the respondents (n=63, 55.8%) reported integrating HLM principles into routine patient assessments, and 80.5% (n=91) of the respondents reported more frequent discussions related to health span–focused care. In addition, 23% (n=26) of the respondents initiated aging biomarker testing, 48.7% (n=55) increased the testing frequency, 52.2% (n=59) reported a shift in their perspective on aging, and 73.5% (n=83) anticipated full integration of HLM into mainstream medicine. Physicians practicing in specialized care demonstrated higher odds of reporting increased confidence in HLM knowledge compared with those in primary and preventive care (odds ratio 4.46, 95% CI 1.55‐12.79; P =.005). Conclusions: Accredited education in HLM is associated with enhanced confidence in HLM knowledge, increased clinical engagement with HLM practices, and a shift in aging-related care paradigms. These findings underscore the critical role of structured HLM curricula in bridging the translational gap between geroscience and everyday medical practice. Nevertheless, systemic health care barriers impede widespread implementation, warranting policy-level strategies to support health span–oriented education and care models.


  • Open Access

    Primary Anti-Phospholipid Antibody Syndrome: Real-World Defining Features of Rethrombosis in the Course of Disease

    by Maria Francisca Moraes-Fontes, Filipa Pedro, Maria Manuel Campos, Melissa Fernandes, Sule Yavuz, Francisco Oliveira, António Panarra

    Objective. We aimed to identify features that allow differentiation of primary antiphospholipid syndrome (PAPS) patients that suffer recurrent thrombotic events (RTE) despite anticoagulation, from the other diagnosed PAPS patients. Methods. This was an exploratory study of anticoagulated PAPS patients attending an Autoimmune Diseases Unit (1998-2018). From 2016, anti-phospholipid antibodies and lupus anticoagulant were determined for each patient at consecutive visits, collected together with retrospective clinical characteristics, laboratory, and therapeutic markers and compared according to the occurrence of thrombotic events during follow-up. Results. Overall, two thirds of the patients were female, 93 were Caucasian, with a median age of 40 years at diagnosis, for a median time of 11.5 years in follow-up. Out of 54 patients, 10 were identified with RTE. There were no significant differences among the RTE and non-RTE patients as far as classical risk factors for clotting disorders. The RTE group was characterized by a higher proportion of younger patients, male sex and positivity for all laboratory markers, and initially and over follow-up as well as a sustained high-risk profile based on APS laboratory markers. Anticardiolipin IgG at onset was the only statistically significant marker of the RTE group. At the end of follow-up, consistent reversion to negative status was a rare event, observed in 20 of RTE vs. 25 of non-RTE patients. Conclusions. Despite therapy, we were able to identify features associated to thrombotic events in patients with PAPS. Prospectively regular clinical and laboratory monitoring might be warranted in order to treat APS more assertively.

  • Open Access

    Systemic Lupus Erythematosus Pregnancy

    by Melissa Fernandes, Vera Bernardino, Anna Taulaigo, Jorge Fernandes, Ana Lladó, Fátima Serrano

    Systemic Lupus Erythematosus (SLE) is an autoimmune disease of unknown etiology that often affects women during childbearing age. Pregnant women with SLE are considered high-risk patients, with pregnancy outcomes being complicated by high maternal and fetal mortality and morbidity. Obstetric morbidity includes preterm birth, fetal growth restriction (FGR), and neonatal lupus syndromes. Active SLE during conception is a strong predictor of adverse pregnancy outcomes and exacerbations of disease can occur more frequently during gestation. Therefore, management of maternal SLE should include preventive strategies to minimize disease activity and to reduce adverse pregnancy outcomes. Patients with active disease at time of conception have increased risk of flares, like lupus nephritis, imposing a careful differential diagnosis of pre-eclampsia, keeping in mind that physiological changes of pregnancy may mimic a lupus flare. Major complications arise when anti-phospholipid antibodies are present, like recurrent pregnancy loss, stillbirth, FGR, and thrombosis in the mother. A multidisciplinary approach is hence crucial and should be initiated to all women with SLE at childbearing age with an adequate preconception counseling with assessment of risk factors for adverse maternal and fetal outcomes with a tight pregnancy monitoring plan. Although treatment choices are limited during pregnancy, prophylactic anti-aggregation and anticoagulation agents have proven beneficial in reducing thrombotic events and pre-eclampsia related morbidity. Pharmacological therapy should be tailored, allowing better outcomes for both the mother and the baby. Immunosuppressive and immunomodulators, must be effective in controlling disease activity and safe during pregnancy. Hydroxychloroquine is the main therapy for SLE due to its anti-inflammatory and immunomodulatory effects recommended before and during pregnancy and other immunosuppressive drugs (e.g. azathioprine and calcineurin inhibitors) are used to control disease activity in order to improve obstetrical outcomes. Managing a maternal SLE is a challenging task, but an early approach with multidisciplinary team with close monitoring is essential and can improve maternal and fetal outcomes.